177 related articles for article (PubMed ID: 24006439)
1. Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations.
Ferreira CB; Merino-Mansilla A; Llano A; Pérez I; Crespo I; Llinas L; Garcia F; Gatell JM; Yuste E; Sanchez-Merino V
J Virol; 2013 Nov; 87(22):12227-36. PubMed ID: 24006439
[TBL] [Abstract][Full Text] [Related]
2. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.
Medina-Ramírez M; Sánchez-Merino V; Sánchez-Palomino S; Merino-Mansilla A; Ferreira CB; Pérez I; González N; Alvarez A; Alcocer-González JM; García F; Gatell JM; Alcamí J; Yuste E
J Virol; 2011 Jun; 85(12):5804-13. PubMed ID: 21471239
[TBL] [Abstract][Full Text] [Related]
3. Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.
Sanchez-Merino V; Fabra-Garcia A; Gonzalez N; Nicolas D; Merino-Mansilla A; Manzardo C; Ambrosioni J; Schultz A; Meyerhans A; Mascola JR; Gatell JM; Alcami J; Miro JM; Yuste E
J Virol; 2016 Jun; 90(11):5231-5245. PubMed ID: 26984721
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity.
Pernas M; Sanchez-Merino V; Casado C; Merino-Mansilla A; Olivares I; Yuste E; Lopez-Galindez C
PLoS One; 2015; 10(8):e0134054. PubMed ID: 26258485
[TBL] [Abstract][Full Text] [Related]
5. An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.
Kumar S; Panda H; Makhdoomi MA; Mishra N; Safdari HA; Chawla H; Aggarwal H; Reddy ES; Lodha R; Kumar Kabra S; Chandele A; Dutta S; Luthra K
J Virol; 2019 Feb; 93(4):. PubMed ID: 30429339
[TBL] [Abstract][Full Text] [Related]
6. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.
Gray ES; Madiga MC; Hermanus T; Moore PL; Wibmer CK; Tumba NL; Werner L; Mlisana K; Sibeko S; Williamson C; Abdool Karim SS; Morris L;
J Virol; 2011 May; 85(10):4828-40. PubMed ID: 21389135
[TBL] [Abstract][Full Text] [Related]
7. Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.
Hu X; Hong K; Zhao C; Zheng Y; Ma L; Ruan Y; Gao H; Greene K; Sarzotti-Kelsoe M; Montefiori DC; Shao Y
J Gen Virol; 2012 Oct; 93(Pt 10):2267-2278. PubMed ID: 22791603
[TBL] [Abstract][Full Text] [Related]
8. Increased frequencies of CD8
Palmer CD; Romero-Tejeda M; Scully EP; Lockhart A; Seaman MS; Goldenthal A; Piechocka-Trocha A; Walker BD; Chibnik LB; Jost S; Porichis F
J Int AIDS Soc; 2016; 19(1):21136. PubMed ID: 27938646
[TBL] [Abstract][Full Text] [Related]
9. Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.
Sajadi MM; Lewis GK; Seaman MS; Guan Y; Redfield RR; DeVico AL
J Virol; 2012 May; 86(9):5014-25. PubMed ID: 22379105
[TBL] [Abstract][Full Text] [Related]
10. HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.
Rouers A; Klingler J; Su B; Samri A; Laumond G; Even S; Avettand-Fenoel V; Richetta C; Paul N; Boufassa F; Hocqueloux L; Mouquet H; Rouzioux C; Lambotte O; Autran B; Graff-Dubois S; Moog C; Moris A;
EBioMedicine; 2017 Jul; 21():158-169. PubMed ID: 28615147
[TBL] [Abstract][Full Text] [Related]
11. Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India.
Vidyavijayan KK; Cheedarala N; Babu H; Precilla LK; Sathyamurthi P; Chandrasekaran P; Murugavel KG; Swaminathan S; Tripathy SP; Hanna LE
Front Immunol; 2018; 9():2841. PubMed ID: 30619250
[No Abstract] [Full Text] [Related]
12. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
[TBL] [Abstract][Full Text] [Related]
13. Detection of Neutralizing Antibodies in HIV-1 Patients on Antiretroviral Treatment for Over Ten Years.
Cao W; Wang X; Li B; Lin L; Du Z; Zhao H; Zhang Y; Xu Z; Qiao Y
Clin Lab; 2019 Jul; 65(7):. PubMed ID: 31307159
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
15. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
Caskey M; Klein F; Lorenzi JC; Seaman MS; West AP; Buckley N; Kremer G; Nogueira L; Braunschweig M; Scheid JF; Horwitz JA; Shimeliovich I; Ben-Avraham S; Witmer-Pack M; Platten M; Lehmann C; Burke LA; Hawthorne T; Gorelick RJ; Walker BD; Keler T; Gulick RM; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC
Nature; 2015 Jun; 522(7557):487-91. PubMed ID: 25855300
[TBL] [Abstract][Full Text] [Related]
16. Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India.
Makhdoomi MA; Khan L; Kumar S; Aggarwal H; Singh R; Lodha R; Singla M; Das BK; Kabra SK; Luthra K
J Gen Virol; 2017 Jul; 98(7):1879-1891. PubMed ID: 28696188
[TBL] [Abstract][Full Text] [Related]
17. Antibodies that cross-neutralize the tier-2 pseudoviruses are produced in antiretroviral-naïve HIV-1-infected children from northern India.
Prakash SS; Andrabi R; Kumar R; Lodha R; Kabra SK; Vajpayee M; Luthra K
Arch Virol; 2012 Sep; 157(9):1797-801. PubMed ID: 22674340
[TBL] [Abstract][Full Text] [Related]
18. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
19. Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.
Chukwuma VU; Kose N; Sather DN; Sapparapu G; Falk R; King H; Singh V; Lampley R; Malherbe DC; Ditto NT; Sullivan JT; Barnes T; Doranz BJ; Labranche CC; Montefiori DC; Kalams SA; Haigwood NL; Crowe JE
PLoS One; 2018; 13(12):e0209437. PubMed ID: 30566528
[TBL] [Abstract][Full Text] [Related]
20. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
